An antiinflammatory effect of salmeterol, a long-acting β2 agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma

American Journal of Respiratory and Critical Care Medicine

Volumn 160, Issue 5 I, 1999, Pages 1493-1499

  Li, Xun ^a   Ward, Chris ^a   Thien, Francis ^a   Bish, Ros ^a   Bamford, Tiffany ^a   Bao, Xianghua ^a   Bailey, Michael ^a   Wilson, John W ^a   Walters, E Haydn ^a  

^a MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE; SALMETEROL;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EOSINOPHIL; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG BIOPSY; LUNG LAVAGE; LYMPHOCYTE ACTIVATION; MACROPHAGE; MALE; MAST CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION;

EID: 0032724631     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.160.5.9811052     Document Type: Article

References (39)

1. Greening, A. P., P. W. Ind, M. Northfield, and G. Shaw. 1994. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid: Allen and Hanburys Limited UK Study Group. Lancet 344(8917):219-224.
2. Pauwels, R. A., C. G. Lofdahl, D. S. Postma, A. E. Tattersfield, P. O'Byrne, P. J. Barnes, and A. Ullman. 1997. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N. Engl. J. Med. 337(20):1405-1411.
3. Lai, C. K., O. P. Twentyman, and S. T. Holgate. 1989. The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the associated change in nonspecific bronchial responsiveness. Am. Rev. Respir. Dis. 140(4):917-923.
4. Sears, M. R., D. R. Taylor, C. G. Print, D. C. Lake, Q. Q. Li, E. M. Flannery, D. M. Yates, M. K. Lucas, and G. P. Herbison. 1990. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 336(8728): 1391-1396.
5. Crane, J., N. Pearce, A. Flatt, C. Burgess, R. Jackson, T. Kwong, M. Ball, and R. Beasley. 1989. Prescribed fenoterol and death from asthma in New Zealand. 1981-83: case-control study. Lancet 1(8644):917-922.
6. Spitzer, W. O., S. Suissa, P. Ernst, R. I. Horwitz, B. Habbick, D. Cockcroft, J. F. Boivin, M. McNutt, A. S. Buist, and A. S. Rebuck. 1992. The use of beta-agonists and the risk of death and near death from asthma. N. Engl. J. Med. 326(8):501-506.
7. Garrett, J. E., S. F. Lanes, J. Kolbe, and H. H. Rea. 1996. Risk of severe life threatening asthma and beta agonist type: an example of confounding by severity. Thorax 51(11):1093-1099.
8. Cheung, D., M. C. Timmers, A. H. Zwinderman, E. H. Bel, J. H. Dijkman, and P. J. Sterk. 1992. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N. Engl J. Med. 327(17):1198-1203.
9. Booth, H., R. Bish, J. Walters, F. Whitehead, and E. H. Walters. 1996. Salmeterol tachyphylaxis in steroid treated asthmatic subjects. Thorax 51(11):1000-1104.
10. Cockcroft, D. W., and V. A. Swystun. 1996. Functional antagonism: tolerance produced by inhaled beta 2 agonists. Thorax 51(10):1051-1056.
11. Johnson, M. 1991. The preclinical pharmacology of salmeterol: non-bronchodilator effects. Eur. Respir. Rev. 1:257-260.
12. Boulet, L. P., H. Turcotte, M. Boutet, J. Dube, M. Gagnon, and M. Lavoilette. 1997. Influence of salmeterol on chronic and allergen-induced airway inflammation in mild allergic asthma - a pilot study. Curr. Ther. Res. Clin. Exp. 58(4):240-259.
13. Gardiner, P. V., C. Ward, H. Booth, A. Allison, D. J. Hendrick, and E. H. Walters. 1994. Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am. J. Respir. Crit. Care Med. 150(4):1006-1011.
14. Kraft, M., S. E. Wenzel, C. M. Bettinger, and R. J. Martin. 1997. The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma. Chest 111(5):1249-1254.
15. Wallin, A., T. Sandstrom, M. Soderberg, P. Howarth, B. Lundback, G. Della-Cioppa, S. Wilson, M. Judd, R. Dukanovic, and S. Holgate. 1998. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. Am. J. Respir. Crit. Care Med. 158:79-86.
16. Richmond, I., H. Booth, C. Ward, and E. H. Walters. 1996. Intrasubject variability in airway inflammation in biopsies in mild to moderate stable asthma. Am. J. Respir. Crit. Care Med. 153(3):899-903.
17. Beach, J. R., C. L. Young, A. J. Avery, S. C. Stenton, J. H. Dennis, E. H. Walters, and D. J. Hendrick. 1993. Measurement of airway responsiveness to methacholine: relative importance of the precision of drug delivery and the method of assessing response. Thorax 48(3):239-243.
18. Littell, R. C., G. A. Milliken, W. W. Stroup, and R. D. Wolfinger. 1996. SAS System for Mixed Models, version 6.12. SAS Institute, Cary, NC.
19. Booth, H., I. Richmond, C. Ward, P. V. Gardiner, R. Harkawat, and E. H. Walters. 1995. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. Am. J. Respir. Crit. Care Med. 152(1):45-52.
20. Djukanovic, R., W. R. Roche, J. W. Wilson, C. R. Beasley, O. P. Twenty-man, R. H. Howarth, and S. T. Holgate. 1990. Musocal inflammation in asthma. Am. Rev. Respir. Dis. 142(2):434-457.
21. Bentley, A. M., G. Menz, C. Storz, D. S. Robinson, B. Bradley, P. K. Jeffery, S. R. Durham, and A. B. Kay. 1992. Identification of T lymphocytes, macrophages, and activated eosinophils in the bronchial mucosa in intrinsic asthma: relationship to symptoms and bronchial responsiveness. Am. Rev. Respir. Dis. 146(2):500-506.
22. Tai, P. C., C. J. Spry, C. Peterson, P. Venge, and I. Olsson. 1984. Monoclonal antibodies distinguish between storage and secreted forms of eosinophil cationic protein. Nature (London) 309(5964):182-184.
23. Jahnsen, F. L., T. S. Halstensen, and P, Brandtzaeg. 1994. Erroneous immunohistochemical application of monoclonal antibody EG2 to detect cellular activation. Lancet 344(8935):1514-1515.
24. Oddera, S., M. Silvestri, R. Testi, and G. A. Rossi. 1998. Salmeterol enhances the inhibitory activity of dexamethasone on allergen-induced blood mononuclear cell activation. Respiration 65(3):199-204.
25. Anenden, V., G. Eqemba, B. Kessel, M. Johnson, J. Costello, and S. Kilfeather. 1998. Salmeterol facilitation of fluticasone-induced apoptosis in eosinophils of asthmatics pre-and post-antigen challenge. Eur. Respir. J. 12:157s.
26. Giuntini, C. G., and P. L. Paggiaro. 1995. Present state of the controversy about regular inhaled beta-agonists in asthma [Editorial]. Eur. Respir. J. 8(5):673-678.
27. Twentyman, O. P., J. P. Finnerty, A. Harris, J. Palmer, and S. T. Holgate. 1990. Protection against allergen-induced asthma by salmeterol. Lancet 336(8727):1338-1342.
28. Pedersen, B., R. Dahl, B. B. Larsen, and P. Venge. 1993. The effect of salmeterol on the early- and late-phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein X. Allergy 48(5):377-382.
29. Taylor, D. R., G. I. Town, G. P. Herbison, D. Boothman-Burrell, E. M. Flannery, B. Hancox, E. Harre, K. Lanbscher, K. Linscott, C. M. Ramsy, and G. Richards. 1998. Asthma control during long term treatment with regular inhaled salbutamol and salmeterol. Thorax 53:744-754.
30. Wilding, P., M. Clark, J. T. Coon, S. Lewis, L. Rushton, J. Oborne, S. Cooper, and A. E. Tattersfield. 1997. Effect of long-term treatment with salmeterol on asthma control: a double blind, randomized crossover study. Br. Med. J. 314(7092):1441-1446.
31. Soler, M., L. Joos, C. T. Bolliger, S. Elsasser, and A. P. Perruchoud. 1994. Bronchoprotection by salmeterol: cell stabilization or functional antagonism? Comparative effects on histamine- and AMP-induced bronchoconstriction. Eur. Respir. J. 7(11):1973-1977.
32. Wempe, J. B., E. P. Tammeling, G. H. Koeter, L. Hakansson, P. Venge, and D. S. Postma. 1992. Blood eosinophil numbers and activity during 24 hours: effects of treatment with budesonide and bambuterol. J. Allergy Clin. Immunol. 90(5):757-765.
33. Weersink, E. J., R. Aalbers, G. H. Koeter, H. F. Kauffman, J. G. De Monehy, and D. S. Postma. 1994. Partial inhibition of the early and late asthmatic response by a single dose of salmeterol. Am. J. Respir. Crit. Care Med. 150(5, Pt. 1):1262-1267.
34. Taylor, I. K., K. M. O'Shaughnessy, N. B. Choudry, M. Adachi, J. B. Palmer, and R. W. Fuller. 1992. A comparative study in atopic subjects with asthma of the effects of salmeterol and salbutamol on allergen-induced bronchoconstriction, increase in airway reactivity, and increase in urinary leukotriene E4 excretion. J. Allergy Clin. Immunol. 89(2):575-583.
35. McIvor, R. A., E. Pizzichini, M. O. Turner, P. Hussack, F. E. Hargreave, and M. R. Scars. 1998. Potential masking effects of salmeterol on airway inflammation in asthma. Am. J. Respir. Crit. Care Med. 158(3): 924-930.
36. Bolton, P. B., P. Lefevre, and D. M. McDonald. 1997. Salmeterol reduces early- and late-phase plasma leakage and leukocyte adhesion in rat airways. Am. J. Respir. Crit. Care Med. 155(4):1428-1435.
37. Eda, R., H. Sugiyama, R. J. Hopp, C. Okada, A. K. Bewtra, and R. G. Townley. 1993. Inhibitory effects of formoterol on platelet-activating factor induced eosinophil chemotaxis and degranulation. Int. Arch. Allergy Immunol. 102(4):391-398.
38. Whelan, C. J., and M. Johnson. 1992. Inhibition by salmeterol of increased vascular permeability and granulocyte accumulation in guinea-pig lung and skin. Br. J. Pharmacol. 105(4):831-838.
39. Anderson, R., C. Feldman, A. J. Theron, G. Ramafi, P. J. Cole., and R. Wilson. 1996. Anti-inflammatory, membrane-stabilizing interactions of salmeterol with human neutrophils in vitro. Br. J. Pharmacol. 117(7): 1387-1394.